- Home
- Publications
- Publication Search
- Publication Details
Title
Management of Idiopathic Pulmonary Fibrosis
Authors
Keywords
-
Journal
ANNALS OF PHARMACOTHERAPY
Volume -, Issue -, Pages 106002801986249
Publisher
SAGE Publications
Online
2019-07-08
DOI
10.1177/1060028019862497
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials
- (2019) Vincent Cottin et al. EUROPEAN RESPIRATORY JOURNAL
- Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis
- (2019) Zuojun Xu et al. ADVANCES IN THERAPY
- Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
- (2018) Carlo Vancheri et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects
- (2018) Doreen Luedtke et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Safety of Nintedanib Added to Pirfenidone Treatment for Idiopathic Pulmonary Fibrosis
- (2018) Kevin R. Flaherty et al. EUROPEAN RESPIRATORY JOURNAL
- Stability or improvement in forced vital capacity with nintedanib in patients with IPF
- (2018) Kevin R Flaherty et al. EUROPEAN RESPIRATORY JOURNAL
- Safety and tolerability of nintedanib in patients with IPF in the United States
- (2018) Imre Noth et al. EUROPEAN RESPIRATORY JOURNAL
- The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
- (2018) Alex Diamantopoulos et al. PHARMACOECONOMICS
- Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece
- (2018) Argyrios Tzouvelekis et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study – Rationale and study design
- (2018) Jürgen Behr et al. RESPIRATORY MEDICINE
- Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
- (2018) Helen E. Jo et al. BMC Pulmonary Medicine
- Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
- (2018) David A Lynch et al. Lancet Respiratory Medicine
- Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- (2018) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
- (2018) Martin Kolb et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
- (2018) Kevin K. Brown et al. RESPIRATORY MEDICINE
- Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
- (2017) Helen E. Jo et al. EUROPEAN RESPIRATORY JOURNAL
- Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
- (2017) Ganesh Raghu EUROPEAN RESPIRATORY JOURNAL
- Combined pulmonary fibrosis and emphysema: bad and ugly all the same?
- (2017) Vincent Cottin EUROPEAN RESPIRATORY JOURNAL
- Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
- (2017) Harold R. Collard et al. EUROPEAN RESPIRATORY JOURNAL
- The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis
- (2017) Vincent Cottin Expert Opinion On Drug Safety
- Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
- (2017) Frank Hilberg et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
- (2017) Michael Kreuter et al. RESPIRATION
- Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry
- (2017) Ian N. Glaspole et al. RESPIROLOGY
- Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions
- (2017) Jonathan A. Galli et al. RESPIROLOGY
- Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
- (2017) Christopher S King et al. Lancet Respiratory Medicine
- Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
- (2017) Steven D Nathan et al. Lancet Respiratory Medicine
- Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
- (2017) Kerri A Johannson et al. Lancet Respiratory Medicine
- Optimizing quality of life in patients with idiopathic pulmonary fibrosis
- (2017) Mirjam J. G. van Manen et al. Therapeutic Advances in Respiratory Disease
- Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments
- (2017) Kelly Fleetwood et al. Journal of Managed Care & Specialty Pharmacy
- Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis
- (2016) Jolene H. Fisher et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011
- (2016) John P. Hutchinson et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
- (2016) Ulrich Costabel et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
- (2016) Harold R. Collard et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Drug Treatment of Idiopathic Pulmonary Fibrosis
- (2016) William J. Canestaro et al. CHEST
- Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations
- (2016) Helen E. Jo et al. DRUGS & AGING
- Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997–2008
- (2016) John P. Hutchinson et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
- (2016) Carlo Albera et al. EUROPEAN RESPIRATORY JOURNAL
- Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer
- (2016) Claudia Dallinger et al. JOURNAL OF CLINICAL PHARMACOLOGY
- First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
- (2016) Wim A. Wuyts et al. LUNG
- A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
- (2016) C. Rinciog et al. PHARMACOECONOMICS
- Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
- (2016) Luca Richeldi et al. RESPIRATORY MEDICINE
- Subgroup analysis of Asian patients in the INPULSIS®trials of nintedanib in idiopathic pulmonary fibrosis
- (2016) Hiroyuki Taniguchi et al. RESPIROLOGY
- Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
- (2016) Steven D Nathan et al. THORAX
- Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
- (2016) Martin Kolb et al. THORAX
- Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis
- (2016) Yanni F. Yu et al. Journal of Managed Care & Specialty Pharmacy
- Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
- (2016) Gareth Hughes et al. Journal of Clinical Medicine
- Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis
- (2016) Michael Kreuter et al. PLoS One
- TOLLIP,MUC5B, and the Response toN-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis
- (2015) Justin M. Oldham et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- (2015) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Outcomes After Hospitalization in Idiopathic Pulmonary Fibrosis
- (2015) A. Whitney Brown et al. CHEST
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
- (2015) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
- (2015) Jürgen Behr et al. EUROPEAN RESPIRATORY JOURNAL
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
- (2015) Paul W. Noble et al. EUROPEAN RESPIRATORY JOURNAL
- A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
- (2015) David Weill et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Be honest and help me prepare for the future
- (2015) Anne E Holland et al. Chronic Respiratory Disease
- Exercise training in idiopathic pulmonary fibrosis
- (2015) Baruch Vainshelboim et al. Expert Review of Respiratory Medicine
- New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses
- (2014) Neil Ahluwalia et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11
- (2014) Ganesh Raghu et al. Lancet Respiratory Medicine
- Pathogenesis of Idiopathic Pulmonary Fibrosis
- (2013) Paul J. Wolters et al. Annual Review of Pathology-Mechanisms of Disease
- New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis
- (2012) Isis E Fernandez et al. LANCET
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary Fibrosis
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
- (2011) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
- (2011) Paul W Noble et al. LANCET
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers
- (2011) Peter Stopfer et al. XENOBIOTICA
- Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis
- (2009) Evans R. Fernández Pérez et al. CHEST
- Adverse effects of anticancer agents that target the VEGF pathway
- (2009) Helen X. Chen et al. Nature Reviews Clinical Oncology
- Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
- (2009) C.M. Rubino et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- An Official American Thoracic Society Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses
- (2008) Paul N. Lanken et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now